期刊文献+

市售阿仑膦酸钠片崩解度、溶出度和食道粘膜黏附量的研究 被引量:1

Comparisons on Disintegration,Dissolution and Esophageal Retention of Commercial Alendronate Tablets
下载PDF
导出
摘要 阿仑膦酸钠为一新型骨质疏松症治疗和预防药物,属第三代二膦酸盐类骨再吸收抑制剂。阿仑膦酸钠生物利用度极低,个体差异大,不同品牌的产品的疗效有一定的差异,另外,阿仑膦酸钠对食道有一定的刺激性,不同品牌的产品的副作用也有较大的差异,其原因可能与不同品牌制剂的内在质量有关系。本文比较了4种不同品牌阿仑膦酸钠片的崩解性、溶出度、片剂颗粒与食道粘膜的黏附。结果显示:4种制剂的崩解、溶出、食道黏附量均有一定的差异,提示4种产品的生物利用度和对食道的副作用可能有一定的差别。该研究对于研究阿仑膦酸钠片质量标准的完善具有一定的意义。 Alendronate [ (4-amino-1-hydroxybutylidene) bisphosphonate ] is an important representative of the bisphosphonates used to treat metabolic disorders of calcium, like Paget's disease of bone, hypercalcemia, and osteoporosis. The oral absorption of alendronate is approximately 0.6% of the administered dose. Alendronate may cause local irritation of the upper gastrointestinal mucosa. Significant differences in bioavailabilitv and local irritation from one brand to another were observed. The present studies aimed to make comparisons of disintegration, dissolution and esophageal retention of Alendronate Tablets from different manufacturers. The results in- dicated that significant differences in disintegration, dissolution and esophageal retention could be observed. And the results could be applicable to predict or explain the differences in efficacy and adverse effects from different commercial products.
出处 《中国药品标准》 CAS 2009年第2期97-101,共5页 Drug Standards of China
关键词 阿仑膦酸钠片 食道粘膜 溶出度 黏附 崩解度 生物利用度 市售 骨质疏松症 Alendronate Tablets disintegration dissolution adverse effects
  • 相关文献

参考文献1

二级参考文献6

  • 107067FDA.批准改良的Fosamax.MKt L,2005,32(16):21-21.
  • 2Kuljanin J, Jankovic I, Nedeljkovic J, et al . Spectrophotometric determination of alendronate in pharmaceutical formulations via complex forraation with Fe(Ⅲ) ions[J]. J Pharm Biomed Anal,2002,28(6) : 1215 - 1220.
  • 3Ptacek P, Klima J, Macek J. Determination of aleadronate in human urine as 9 - fluorenylmethyl derivative by high - performance liquid chromatography[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2002,767( 1 ) : 111 - 116.
  • 4Tsai EW, Singh MM, Lu HH, et al. Application of capillary electrophoresis to phammceutical analysis - determination of alendronate in dosage forms [J] .J Chromatogr, 1992,626:245.
  • 5Reed DG, Martin GP, Konieczny JM, et al. The determination of alendronate sodium in tablets by inductively coupled plasma(ICP)[J].J Pharm Biomed Anal,1995,13(8) :1055 - 1058.
  • 6Elham Anwer TAHA, Nadia Fayek YOUSSEF. Spectrophotometric determination some drugs osteoporosis [ J ]. Chem Pharm Bull,2003,51(12) :1444- 1447.

共引文献5

同被引文献16

  • 1龙明立,黄红林,沈元琼,靳守东,刘文尧.比色法测定复方阿仑膦酸钠缓释片中阿仑膦酸钠的含量[J].南华大学学报(医学版),2007,35(1):101-103. 被引量:6
  • 2Saad F.Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma[J].Eur Urol Suppl,2007,6(11):683-688.
  • 3Molinuevo MS,Bruzzone L,Cortizo AM.Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells[J].Eur J Phatmacol,2007,562(1-2):28-33.
  • 4Bolanos Díaz R.Comment on disintegration/dissolution profiles of copies of Fosamax (alendronate)[J].Curr Med Res Opin,2004,20(7):1035-1036.
  • 5Dansereau RJ,Crail D J,Perkins AC.In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 rag) and in vivo implications[J].Curr Med Res Opin,2008,24(4):1137-1145.
  • 6Ptacek P,Klima J,Macek J.Determination of alendronate in human urine as 9-fluorenylmethyl derivative by high-performance liquid chromatography[J].J Cbromatogr B Analyt Technol Biomed Life Sci,2002,767(1):111-116.
  • 7Kang HS,Hwang S J,Park JS,et al.HPLC method validation and pharmacokinetic study of alendronate sodium in human urine with fluorescence detection[J].J Liq Chromatogr RT,2006,29(11):1589-1600.
  • 8Yun MH,Kwon KI.High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence:application to a pharmacokinetic study in humans[J].J Pharm Biomed Anal,2006,40(1):168-172.
  • 9Andréia DHM,Helena RP,Leonardo P.Potentiometric determination of alendronate in pharmaceutical formulations[J].Chemia analityczna,2004,49(3):351-357.
  • 10Han YH,Qin XZ.Determination of alendronate sodium by ion chromatography with refractive index detection[J].J Chromatogr A,1996,719(2):345-352.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部